Palmitoylations on Murine Coronavirus Spike Proteins Are Essential for Virion Assembly and Infectivity

Edward B. Thorp,† Joseph A. Boscarino, Hillary L. Logan, Jeffrey T. Goletz, and Thomas M. Gallagher*

Department of Microbiology and Immunology, Loyola University Medical Center, Maywood, Illinois 60153

Received 22 June 2005/Accepted 11 November 2005

Coronavirus spike (S) proteins are palmitoylated at several cysteine residues clustered near their transmembrane-spanning domains. This is achieved by cellular palmitoyl acyltransferases (PATs), which can modify newly synthesized S proteins before they are assembled into virion envelopes at the intermediate compartment of the exocytic pathway. To address the importance of these fatty acylations to coronavirus infection, we exposed infected cells to 2-bromopalmitate (2-BP), a specific PAT inhibitor. 2-BP profoundly reduced the specific infectivities of murine coronaviruses at very low, nontoxic doses that were inert to alphavirus and rhabdovirus infections. 2-BP effected only two- to fivefold reductions in S palmitoylation, yet this correlated with reduced S complexing with virion membrane (M) proteins and consequent exclusion of S from virions. At defined 2-BP doses, underpalmitoylated S proteins instead trafficked to infected cell surfaces and elicited cell-cell membrane fusions, suggesting that the acyl chain adducts are more critical to virion assembly than to S-induced syncytial developments. These studies involving pharmacologic inhibition of S protein palmitoylation were complemented with molecular genetic analyses in which cysteine acylation substrates were mutated. Notably, some mutations (C1347F and C1348S) did not interfere with S incorporation into virions, indicating that only a subset of the cysteine-rich region provides the essential S-assembly functions. However, the C1347F/C1348S mutant viruses exhibited relatively low specific infectivities, similar to virions secreted from 2-BP-treated cultures. Our collective results indicate that the palmitate adducts on coronavirus S proteins are necessary in assembly and also in positioning the assembled envelope proteins for maximal infectivity.

Palmitoylation is a common posttranslational modification that can influence protein trafficking and protein-protein and protein-membrane interactions. The hydrophobic acyl chains are linked to thioesterification reactions to cysteine residues residing in the cytoplasmic tails of several viral membrane glycoproteins, including the influenza virus hemagglutinin, paramyxovirus F, vesicular stomatitis virus (VSV) G, Sindbis virus (SV) E1, retrovirus Env, baculovirus gp64, and coronavirus spike (S). The importance of these lipid modifications to viral glycoprotein structure is not precisely known; however, it is reasonable to assume that they act to position cytoplasmic membrane-spanning domains. This is achieved by cellular palmitoyl acyltransferases (PATs), which can modify newly synthesized S proteins before they are assembled into virion envelopes at the intermediate compartment of the exocytic pathway (34). In the cellular exocytic pathway, this occurs following the Golgi furin-like proteases into two similarly sized 90-kDa fragments, termed S1 and S2 (10). The carboxy-terminal S2 fragments are embedded into virion and infected-cell membranes, and at the boundaries between transmembrane spans and cytoplasmic tails, those from all serogroups have a region containing 7 to 10 cysteine residues within an 18- to 22-amino-acid stretch (see Fig. 9A). More than one of these cysteines are modified by palmitoylation (2), but the exact acylated residues are not yet known for any coronavirus.

The conservation of this remarkably dense cluster of cysteines clearly suggests an important functional relevance. In beginning this study, we hypothesized that palmitates in this region were crucial for virus assembly. Coronaviruses assemble intracellularly, with complete particles budding into the lumen of the endoplasmic reticulum (ER) and cis-Golgi apparatus.
Coronavirus strains JHM (prototype strain MHV-4) (52), JHM-X (22), and A59 (36) were plaque purified three times on HeLa-CEACAM cells and subsequently propagated after a 1-h adsorption on 17c11 cells at a low multiplicity of infection (0.01 PFU/cell) in serum-free medium with 0.01% (wt/vol) bovine serum albumin. Inoculums were replaced with growth medium containing 2% ΔFBS and cell supernatant harvested at 18 h postinfection (hpi), followed by clarification of medium by differential centrifugation to remove cellular debris (sequential spins of 15 min at 2,000 × g followed by 30 min at 10,000 × g).

Infectivities were determined by plaque assay, using either HeLa-CEACAM or 17c11 as indicator cells in DMEM–1% ΔFBS and 0.5% (wt/vol) Noble agar (Difco). Vaccinia virus recombinants vTF7.3 (13) and vTM1-S-JHMX (20), encoding S of strain JHM, were generated and propagated in RK13 cells as described previously (20). VSV and SV were propagated in BHK cells after a low multiplicity of infection and collected from cells after the first signs of cytopathic effect. VSV and SV were clarified as described above for MHV by differential centrifugation prior to application onto cell monolayers.

Recombinant viruses. Targeted RNA recombination (21) was used to create site-directed mutant MHV recombinants. To maximize the potential recognition of site-directed mutants with impaired membrane fusion functions, we used plasmids and parental recombinant MHVs derived from the highly syncytial JHM strain (27). Briefly, plasmid pGSS4 (30), encoding the S protein from MHV JHM (denoted in reference 26 as the “SD” or San Diego JHM strain), was mutated at codon 310 to create G310S. The G310S mutation stabilizes S1-S2 connections, thereby retaining complete S1-S2 complexes during virion purification procedures (26). Mutagenic primers encoding portions of the cysteine-rich region were then used in a series of PCRs to create fragments with missense changes at S codons 1344 (C to S), 1347 (C to S), and 1348 (C to F). A silent V34G substitution was also engineered at codon 310 to simplify subsequent mutagenesis of the cysteine-rich region. A series of mutant S cDNAs was then excised from the pGSS4 plasmids with AvrII and SbfI and used to replace the corresponding regions in pJHM-CA (26), yielding the separate plasmids pJHM-G310S, pJHM-G310S/C1348F, pJHM-G310S/C1347S/C1348F, pJHM-G310S/C1348S/C1347S/C1348F. These plasmid DNAs were linearized by digestion with PacI and used as templates for in vitro transcription reactions. cDNA transcripts, containing T7 RNA polymerase and mMessage mMachine reagents (Ambion, Inc., Austin, TX). In vitro transcripts representing the 3′ 9,336 nucleotides of the MHV genome (∼10 μg of each mutant transcript) were electroporated into ∼107 feline FCWF cells that were infected 6 h earlier with recombinant coronavirus feline MHV-JHM (21, 27), using a Bio-Rad Gene Pulser II. The electroporated FCWF cells (∼107) were then added to T25 flasks seeded with ∼104 murine 17c11 cells. Recombinant JHM viruses were identified by the development of syncytia in the 17c11 monolayers and then isolated by three cycles of plaque purification on 17c11 cells. All site-directed mutations were confirmed by sequencing the relevant cDNA fragments.

Infections and metabolic labeling. Infections were carried out on monolayer cultures, typically ∼107 17c11 cells per cm². At various times postinfection, media were removed and cells rinsed with ice-cold labeling medium containing 25 mM mycophenolic acid, 250 μM xanthine, 20 μM hypoxanthine, and 0.01% bovine serum albumin. Virions were equilibrated at the 30%-50% sucrose interface, typically using a Beckman Spincouper SW28 rotor at 28,000 rpm for 4 h, and recovered by fractionation from air-gradient interfaces. In some experiments, the a59-containing fractions were diluted with HNB, subjected to an additional round of purification on fresh sucrose gradients, and then concentrated by pelleting through 30% sucrose cushions. Purified virions were resuspended in HN buffer (50 mM HEPES [pH 7.4], 100 mM NaCl) and stored at 4°C in sealed glass vials.

Materials and methods. Cells and viruses. All cell lines were propagated as adherent monolayer cultures. Murine 17c11 fibroblasts (42) were grown in Dulbecco’s modified Eagle medium (DMEM) containing 5% tryptose phosphate broth (Difco Laboratories) and 5% heat-inactivated fetal bovine serum (FBS) and cell supernatant harvested at 18 h postinfection (hpi), followed by clarification of medium by differential centrifugation to remove cellular debris (sequential spins of 15 min at 2,000 × g followed by 30 min at 10,000 × g). Infectivities were determined by plaque assay, using either HeLa-CEACAM or 17c11 as indicator cells in DMEM–1% ΔFBS and 0.5% (wt/vol) Noble agar (Difco). Vaccinia virus recombinants vTF7.3 (13) and vTM1-S-JHMX (20), encoding S of strain JHM, were generated and propagated in RK13 cells as described previously (20). VSV and SV were propagated in BHK cells after a low multiplicity of infection and collected from cells after the first signs of cytopathic effect. VSV and SV were clarified as described above for MHV by differential centrifugation prior to application onto cell monolayers.

Recombinant viruses. Targeted RNA recombination (21) was used to create site-directed mutant MHV recombinants. To maximize the potential recognition of site-directed mutants with impaired membrane fusion functions, we used plasmids and parental recombinant MHVs derived from the highly syncytial JHM strain (27). Briefly, plasmid pGSS4 (30), encoding the S protein from MHV JHM (denoted in reference 26 as the “SD” or San Diego JHM strain), was mutated at codon 310 to create G310S. The G310S mutation stabilizes S1-S2 connections, thereby retaining complete S1-S2 complexes during virion purification procedures (26). Mutagenic primers encoding portions of the cysteine-rich region were then used in a series of PCRs to create fragments with missense changes at S codons 1344 (C to S), 1347 (C to S), and 1348 (C to F). A silent V34G substitution was also engineered at codon 310 to simplify subsequent mutagenesis of the cysteine-rich region. A series of mutant S cDNAs was then excised from the pGSS4 plasmids with AvrII and SbfI and used to replace the corresponding regions in pJHM-CA (26), yielding the separate plasmids pJHM-G310S, pJHM-G310S/C1348F, pJHM-G310S/C1347S/C1348F, pJHM-G310S/C1348S/C1347S/C1348F. These plasmid DNAs were linearized by digestion with PacI and used as templates for in vitro transcription reactions. cDNA transcripts, containing T7 RNA polymerase and mMessage mMachine reagents (Ambion, Inc., Austin, TX). In vitro transcripts representing the 3′ 9,336 nucleotides of the MHV genome (∼10 μg of each mutant transcript) were electroporated into ∼107 feline FCWF cells that were infected 6 h earlier with recombinant coronavirus feline MHV-JHM (21, 27), using a Bio-Rad Gene Pulser II. The electroporated FCWF cells (∼107) were then added to T25 flasks seeded with ∼104 murine 17c11 cells. Recombinant JHM viruses were identified by the development of syncytia in the 17c11 monolayers and then isolated by three cycles of plaque purification on 17c11 cells. All site-directed mutations were confirmed by sequencing the relevant cDNA fragments.

Infections and metabolic labeling. Infections were carried out on monolayer cultures, typically ∼107 17c11 cells per cm². At various times postinfection, media were removed and cells rinsed with ice-cold labeling medium containing 25 mM mycophenolic acid, 250 μM xanthine, 20 μM hypoxanthine, and 0.01% bovine serum albumin. Virions were equilibrated at the 30%-50% sucrose interface, typically using a Beckman Spincouper SW28 rotor at 28,000 rpm for 4 h, and recovered by fractionation from air-gradient interfaces. In some experiments, the a59-containing fractions were diluted with HNB, subjected to an additional round of purification on fresh sucrose gradients, and then concentrated by pelleting through 30% sucrose cushions. Purified virions were resuspended in HN buffer (50 mM HEPES [pH 7.4], 100 mM NaCl) and stored at 4°C in sealed glass vials.
We found that 2-BP at doses up to 12 μM had little effect on VSV or Sindbis virus infections (Fig. 1); this was an expected finding given that site-directed mutation of the palmitoylation sites in these viruses does not impair their infectivities (47) (51). In our initial experiments, we applied 2-bromopalmitate (2-BP), a general inhibitor of protein palmitoylation (51), to murine fibroblast cells (17cl1) monolayers (10^5 cells/cm^2) were inoculated with the indicated RNA concentrations of 2-BP. Fifteen hours later, media were removed, and infectivities were determined by plaque titration using 17cl1 cell monolayers as indicator cells.

To determine whether 2-BP blocked production or secretion of MHV particles, media from 35S-labeled cultures were collected with isokinetic saline, chilled to 4°C, and dissolved in ice-cold TNE-TX100 (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 1 mM EDTA, 1% Triton X-100) to 10^7 cells/ml. After 30 min at 4°C, cell extracts were passed five times through a 27-gauge needle and centrifuged (700 g, 30 min at 4°C), cell extracts were passed five times through a 27-gauge needle and centrifuged (700 g, 30 min at 4°C) to remove nuclei. Postnuclear supernatants were mixed with equal volumes of 80% (wt/vol) sucrose in TNE-1% TX100 containing 0.1% protease inhibitor (Sigma), were placed in ultracentrifuge tubes, and overlaid sequentially with 7 ml of 38 or 30% (wt/vol) (as indicated) and 2.5 ml of 5% (wt/vol) sucrose in TNE. Following centrifugation at 4°C for 18 h at 285,000 g in a Beckman SW41 rotor, fractions were collected from air-gradient interfaces. Aliquots of each fraction were then mixed with SDS solubilizer (final concentration, 63 mM Tris-HCl [pH 6.8], 2% [wt/vol] sodium dodecyl sulfate, 2.5% [wt/vol] Ficoll, 0.0025% [wt/vol] bromophenol blue, 5% [vol/vol] 2-mercaptoethanol), heated at 95°C for 5 min, and processed by SDS-PAGE and immunoblotting. To assess the solubilization and fractionation of cell membranes during preparation of DRMs, the standards transferrin receptor and ganglioside GM1 were detected in gradient fractions using anti-transferrin receptor antibodies and cholera toxin-peroxidase conjugate, respectively (16). In assays designed to specifically detect only those S proteins on the plasma membrane, cells were exposed to sulfo-NHS-biotin from Pierce Corporation (catalog no. 21335). Cells were suspended in a minimal volume of phosphate-buffered saline (PBS) (pH 8.0), biotinylated (1 mg/ml biotin) at 4°C for 20 min, and further rinsed three times in cold 30 mM Tris-containing buffer at pH 8.0 to quench unreacted biotin. Cells were subsequently rinsed with ice-cold PBS and subjected to TX-100 extraction and fractionation as aforementioned. Biotinylated proteins were captured with streptavidin-Sepharose beads and processed by immunoblotting as described above.

### RESULTS

**Effect of 2-BP on MHV infectivities.** In our initial experiments, we applied 2-bromopalmitate (2-BP), a general inhibitor of protein palmitoylation (51), to murine fibroblast cells that had been inoculated with various enveloped viruses. After overnight incubations, media were then removed for infectivity determinations. We found that 2-BP at doses up to 12 μM had little effect on VSV or Sindbis virus infections (Fig. 1); this was an expected finding given that site-directed mutation of the palmitoylation sites in these viruses does not impair their infectivities (39, 53). In sharp contrast, coronavirus MHV (strain JHMX) infections were potently inhibited, with doses as low as 0.1 μM reducing yields by fivefold and with 1,000- to 10,000-fold-reduced infectivities at the highest, 12-μM doses (Fig. 1). These 2-BP doses effecting significant infectivity reductions were extraordinarily low, being about 100 to 1,000 times lower than those typically used to generally block protein palmitoylations (47) (51).

![FIG. 1. Effect of 2-BP on virus infectivities. 17cl1 murine fibroblast monolayers (10^5 cells/cm^2) were inoculated with the indicated RNA viruses at 0.1 PFU per cell. At 1 h postinfection, media were aspirated and replaced with fresh growth media containing the indicated concentrations of 2-BP. Fifteen hours later, media were removed, and infectivities were determined by plaque titration using 17cl1 cell monolayers as indicator cells.](http://jvi.asm.org/)

Downloaded from http://jvi.asm.org on May 1, 2015 by INST OF MOLECULAR & CELL BIO
Effect of 2-BP on S protein-M protein interactions. To explain these phenomena, in which particle infectivities declined as syncytia increased, we hypothesized that 2-BP very effectively inhibited ER-localized PAT activities, leaving newly synthesized, uncleaved S proteins underpalmitoylated and unable to participate properly in the virion assembly reactions taking place at the cis-Golgi complex (19). Some of these underpalmitoylated S proteins would then remain with infected cells, perhaps advancing through the exocytic pathway to plasma membranes, thus modestly increasing syncytia in a narrow range of 2-BP drug exposure (Fig. 3).

This hypothesis contends that S proteins are depleted in the virions secreted from 2-BP-treated cells, a reasonable possibility given that S proteins are dispensable for MHV particle assembly and secretion (49). Absence of S would not be apparent from the results shown in Fig. 2, because they comprise a very small fraction of the $^{35}$S radioactivity in MHV particles. Therefore, we evaluated the effect of 2-BP on S protein secretion by collecting media and dissolving cell monolayers in a series of 2-BP-treated, MHV A59-infected cultures. S proteins were then captured using N-CEACAM-Fc (14) and imaged by Western immunoblotting. As predicted, the immunoblots revealed that 2-BP did not block S-protein synthesis and accumulation but did block secretion into media (Fig. 4). Quantifications obtained by titrating the samples in subsequent immunoblot assays (data not shown) indicated that the cell-associated proportion of S proteins steadily rose with increased 2-BP dose, from $\sim$60% to $\sim$95%, while the proportion of S proteins in media correspondingly declined from $\sim$40% to $\sim$5%. These data were consistent with the hypothesis that underpalmitoylated S proteins are excluded from virions and

FIG. 2. Effect of 2-BP on MHV-specific infectivities. MHV-infected 17cl1 cells (multiplicity of infection = 2) were incubated from 1 to 16 hpi with the indicated 2-BP doses. Media were then removed and replaced with $^{35}$S-labeling media containing the same 2-BP concentrations. Four hours later, media were collected and $^{35}$S-labeled virions purified on sucrose density gradients. Banded $^{35}$S-labeled virions were quantitated by scintillation spectrometry and radioactive virus yields plotted relative to controls. Specific infectivities of purified virions (PFU/$^{35}$S cpm) were determined by plaque assay on 17cl1 cells and plotted relative to control values. In the absence of 2-BP, A59- and JHMX-specific infectivities were 2.06 and 1.55 PFU/$^{35}$S cpm, respectively.

FIG. 3. Effect of 2-BP on MHV-induced syncytia. MHV (strain JHMX)-infected 17cl1 cells were incubated from 1 to 16 hpi with the indicated micromolar concentrations of 2-BP and photographed by phase-contrast microscopy. Inset in panel A depicts uninfected cells.
were further addressed by inspecting electropherograms depicting \(^{35}\)S-labeled virion proteins. From virions secreted during a 16- to 20-hpi \(^{35}\)S-labeling period, we found that the relative proportion of S proteins did indeed decline with increasing 2-BP exposure (Fig. 5), as measured relative to virion M and N proteins. The absence of S proteins from virions was more pronounced than that observed for medium-associated S at 9 hpi (Fig. 4), and we suspect that this stems from the longer 2-BP exposures that took place prior to the virion radiolabeling process. This failure to incorporate S proteins into virions is a likely contributor to the low specific infectivity of virions secreted from 2-BP-treated cells (Fig. 2).

A possible explanation for the interference with S protein incorporation into secreted virions appeals to disruption of S protein interaction with M proteins, since S-M intracellular complexes are generally considered to be essential assembly intermediates. Thus, we infected cultures in graded doses of 2-BP, collected media, and then dissolved cell monolayers in a buffer containing both NP-40 and DOC. This detergent formulation is known to dissolve cell membranes while preserving associations between S and M proteins (28). Immunoprecipitations were then employed to capture free S and S-M complexes, which were subsequently imaged by Western immunoblotting. Indeed, the poor incorporation of S proteins into virions correlated with their failure to associate with M proteins (Fig. 6). This was most evident in cultures incubated with the higher 5 and 10 \(\mu\)M 2-BP doses but could be observed in JHMX-infected cells incubated with as little as 1 \(\mu\)M 2-BP.

The 2-BP drug exposures did not exert any direct effects on the synthesis or assembly competence of the M proteins themselves, as evidenced by the abundant M (and N) proteins in secreted virions (Fig. 5). Therefore, this pharmacologic approach with 2-BP suggested that S protein palmitoylation is a prerequisite for its binding to M proteins and consequently for its effective incorporation into virions.

**Effect of 2-BP on S protein palmitoylation.** Given its extreme effects during MHV infection, we expected that we could measure the extent to which 2-BP might interfere with protein...
were incubated from 1 to 16 hpi with the indicated 2-BP doses and declines in the [3H]palmitate labeling of uncleaved S proteins on SDS gels by fluorography. Then lysed cells, immunoprecipitated S proteins, and visualized with [3H]palmitate, using the more robust strain A59 to foster palmitoylations (48). To this end, we again established infected acrylamide gels. S-agg, aggregated S oligomers; S-unc, uncleaved S; S proteolytic fragments; MW, molecular weights in thousands.

Fig. 7. Effect of 2-BP on incorporation of [3H]palmitate onto S proteins. 17c11 cells infected with A59 (multiplicity of infection = 2) were incubated from 1 to 16 hpi with the indicated 2-BP doses and then pulse labeled with [3H]palmitate from 16 to 20 hpi, maintaining the indicated 2-BP concentrations throughout. Cells were dissolved in NP-40 buffer, and S proteins were immunoprecipitated from clarified lysates using magnetic protein A-NCEA-Fc beads. Radioactive S proteins were imaged by fluorography after electrophoresis on SDS-polycrylamide gels. S-agg aggregated S oligomers; S-unc, uncleaved S; *, S proteolytic fragments; MW, molecular weights in thousands.

Palmitoylations (48). To this end, we again established infected 17c11 cultures in graded doses of 2-BP and radiolabeled them with [3H]palmitate, using the more robust strain A59 to foster detection of the weak 3H label. At the peak of infection, we then lysed cells, immunoprecipitated S proteins, and visualized them on SDS gels by fluorography.

Increasing doses of 2-BP correlated with relatively nominal declines in the [3H]palmitate labeling of uncleaved S proteins (Fig. 7) to levels about 10 to 15% of the control level at the 10 μM dose. This decreasing S-protein acylation was consistent with the hypothesis that ER-localized PAT activities are inhibited by 2-BP, since uncleaved S proteins are substrates for palmitoylation in the ER. In conjunction with the results of Fig. 4 to 6, these data also demonstrated that even modest declines in S-protein palmitoylation created dramatic losses in their virion incorporation. The decreasing levels of uncleaved S palmitoylation also correlated with increasing amounts of cell-associated, [3H]palmitoylated proteolytic fragments of molecular weights lower than that of S2 (Fig. 7, note the bands adjacent to the asterisk), suggesting that underpalmitoylated S proteins encounter cellular proteases. The collective findings provided evidence that even modestly underpalmitoylated S proteins are faulty subunits that do not engage in virion assembly.

Effect of 2-BP on distribution of cell-associated S proteins. Our data suggested that underpalmitoylated S proteins transit to infected cell surfaces even in the presence of 10 μM 2-BP (Fig. 7) but then fail to elicit cell-cell fusions (Fig. 3E and F). To explain this significant inhibition of S-mediated syncytia occurring after exposure to relatively high doses of 2-BP, we addressed the hypothesis that S protein palmitates influence the abundance or distribution of S proteins on infected cell surfaces. Indeed, protein modification with multiple palmitates may increase partitioning into lipid rafts (1), making it reasonable to speculate that S proteins produced in the presence of high 2-BP doses might not be condensed into lipid rafts, thereby reducing their ability to cooperate in syncytial developments. This idea was first investigated by determining whether any S proteins were in fact associated with lipid rafts. DRMs are generally viewed as in vitro correlates of dynamic lipid rafts (31); therefore, we isolated these membrane fractions by floatation in sucrose gradients. Our results indicated that a small but significant proportion of cell-associated S proteins were in our DRM fractions, both in MHV-infected cells (Fig. 8A) and in cells infected with a vaccinia virus encoding MHV S proteins (Fig. 8B). In this regard, the S proteins were set apart from the VSV G proteins, which are generally used as indicators of raft exclusion (Fig. 8C) (37). Notably, low-density DRM fractions contained both uncleaved S and cleaved S fragments (Fig. 8B), suggesting an early, pre-trans-Golgi entrance of S proteins into lipid microdomains.

Having demonstrated that a portion of S proteins were indeed embedded in DRMs, we pursued the question of whether 2-BP redistributes membrane associations. For these experiments, we restricted analyses to S proteins on the plasma membrane, using a non-membrane-permeative protein biotinylation agent to modify exposed ectodomains prior to S immunoprecipitation and detection of the biotin tags on Western blots. Cell surface biotinylated S proteins were detected in the 2-BP-treated cultures at levels similar to those of control cultures undergoing cell-cell fusions (data not shown), indicating that the absence of syncytia in 2-BP-treated cultures (Fig. 3E and F) could not be explained by failure of S transport. Floatation of membranes in sucrose gradients revealed that the cell surface S proteins in cultures exposed to 2-BP were largely in the high-density, TX100-soluble material, unlike control S proteins, where ~30% were DRM associated (Fig. 8D to F). Therefore, we suggest that S-protein palmitoylations are necessary to condense free S proteins into lipid raft microdomains, where they cooperate to mediate syncytia. This lipid raft partitioning would have considerable biological relevance for those coronaviruses exhibiting pH-independent S-mediated fusion activities, since this would allow infections to spread via cell-cell fusions.

Molecular genetic evidence for the contribution of palmitoylated cysteines to virus infectivity. Using the pharmacologic approach involving 2-BP, we obtained evidence that palmitoylations were necessary for assembly of S proteins into virions. To determine whether all of the acylated thiols are involved in these assembly reactions or whether some are alternatively necessary only for postassembly functions, we employed a complementary molecular genetic approach in which individual cysteine substrate sites were mutated. This was not a trivial undertaking, because the number of potentially palmitoylated
cysteines at the boundary between S protein transmembrane and cytoplasmic domains is very large (Fig. 9A) and the amino acid chosen to replace each cysteine can generate unexpected outcomes. Additionally, the profoundly disabling effects of 2-BP made it likely that most if not all cysteine mutants would compromise infectivities, perhaps to an extent precluding their isolation. We did, however, have the advantage of earlier results by Bos et al. (2) and Chang et al. (7) revealing some correlations between murine coronavirus S protein acylation and specific infectivities. Two independent determinations revealed infectivities for the thiols themselves or their attached acyl chains are intrinsic contributors to virion architecture and infectivity.

**DISCUSSION**

All coronaviruses encode S proteins with cysteine-rich cytoplasmic tails (6). The essential nature of the cysteine-rich region is suggested by its strict conservation and by the fact that more than one of the thiols are substrates for posttranslational palmitoylation (2). Important molecular genetic analyses have indeed pointed toward the essential roles for the cysteine-rich region in S functions (3, 54), specifically in mediating membrane fusion (2, 7). In this study, we used a pharmacologic approach to discover roles for the posttranslational palmitoylation of the cytoplasmic cysteines of the coronavirus proteins. Using 2-BP to interfere with cellular PAT activities, we established correlations between murine coronavirus S protein acylation, S-protein–M-protein interaction, and infective virion assembly. Therefore, we suggest that it is not the cysteines per se that are relevant to assembly, but it is rather that they act as substrates for palmitoylation and that one or more of the hydrophobic acyl chains are essential components of assembly-competent S proteins. Coronavirus assembly and budding occurs in the ER or cis-Golgi complex (19); therefore, we further suggest that ER or cis-Golgi-localized PAT activities are essential components of the coronavirus-permissive cell.
Our investigations uncovered interesting effects of 2-BP on MHV infection parameters. In MHV-infected 17c1 cells, extraordinarily low 2-BP doses had significant inhibitory effects on infective virion secretion but actually enhanced S-mediated intercellular fusions. This condition was met when total S-protein palmitoylation levels were reduced by ~40%. Thus, when PAT activities are only modestly reduced, the infection shifts from a productive one in which virions are secreted to an overtly cytopathic, syncytial condition that sheds noninfectious virus particles. From these results, we suggest that one or more of the fatty acids on S proteins are more crucial to the virus assembly process than they are to S-induced syncytial developments. This suggestion assumes that 2-BP indiscriminately inhibits PAT activities at sites in the exocytic pathway that are both proximal and distal to the virus budding site. Indeed, it remains possible that 2-BP preferentially blocks...
ER-localized PATs, thus accounting for its antivirion specificity at low doses. If this were the case, we would favor a slightly different view in which coronavirus infection patterns depend on the subcellular distribution of PAT activities. Abundant ER/cis-Golgi-localized PAT would correlate with efficient infective virion assembly and secretion, while distally located Golgi/plasma membrane PATs could only assist in creating syncytial developments. A corollary suggestion is that ER-localized PAT activities regulate the segregation of S proteins between assembling virions and infected-cell surfaces.

Exposure of MHV-infected 17cl1 cells to higher doses of 2-BP abrogated S-mediated syncytial activities. 2-BP did not arrest S transport to cell surfaces; in fact, the opposite occurred as the underpalmitoylated S proteins were not trapped intracellularly in association with M. However, the underpalmitoylated S proteins were partitioned out of DRMs. From these findings, we suggest a secondary role for S-protein palmitoylations, namely, to enhance affinity for lipid raft localization on cell surfaces. We contend that this is a secondary function of acyl groups that is independent of their role during virion assembly. Multiple closely spaced acylations are well-known structures providing for lipid raft partitioning (25, 33). Similarly, we expected that S redistribution out of raft locations would correlate with diminished syncytia. Viral glycoprotein clustering is generally considered to be a prerequisite for the cooperative process by which membrane fusion pores are created (8, 43). Therefore, we are presently favoring a view in which palmitoylations act to cluster S proteins on plasma membranes enough for their cooperative action in fusing opposing membranes. However, our data do not distinguish whether the loss of syncytial activity is intrinsic to underpalmitoylated S proteins or is merely secondary to their dispersion on cell surfaces.

On membrane proteins, two thiols are known to be sufficient for multiple acylation and subsequent lipid raft partitioning (33), but the cytoplasmic tails of coronavirus S proteins, without exception, have 7 to 10 cysteines (6) (Fig. 9A). Thus, the cysteine-rich regions on S proteins appear to have expanded beyond the level necessary for lipid raft partitioning and fusion activity at infected-cell surfaces. We suggest that the expansive cysteine-rich regions have evolved in response to cellular limitations for ER-localized PAT activities. A display of dense cysteine clusters is perhaps the only way to insure that a sufficient portion of newly synthesized S proteins are palmitoylated enough to serve as proper virion assembly subunits. In support of this view, we note that virion assembly competence is universally required but syncytial competence is not. For example, severe acute respiratory syndrome-associated coronavirus infections are not normally syncytial because the S proteins are fusion active at pH values below those found in extracellular fluids (38). Evolutionary selection for cell surface S protein clustering into fusion-active arrangements is therefore unlikely.

2-BP exposures reduced the levels of S proteins in secreted virions, but the cysteine substitution mutations C1347F and C1348S did not. Notably, eliminating these two thiols does not prevent all S acylation (2), and so we suggest that a subset of the S cytoplasmic cysteines serve as the crucial preassembly acylation substrates—cysteines 1347 and 1348 are clearly not included in this subset. We believe that the essential subset minimally includes C1344, since we were never successful at fixing amino acid substitutions at this position into viable recombinant MHVs (data not shown). More extensively mutagenized constructs with substitution of all nine cysteines in the palmitoylation substrate (Fig. 9A) were similarly incompatible with viability. We note that a definitive identification of the acylation substrates required for assembly will have to await results of assays for mutant S-protein incorporation into coronavirus-like particles (3, 11), since we cannot base firm conclusions solely on the basis of negative outcomes from recombinant virus preparation.

While cysteines 1347 and 1348 are dispensable in assembly, they are nonetheless key contributors of native virion structure and robust virus particle infectivity. On the basis of earlier findings by Bos et al. (2), we believe that one or both of these cysteines are palmitoylation substrates, and so we suggest that these S acylations specifically contribute to infectivity at steps distinct from virus assembly. How might these multiple acylations contribute to particle infectivities? An interesting speculation is that the abundant acyl chains linked to the three cytoplasmic tails of each S2 trimer assist in creating lipid bilayer “rings,” insuring relatively high lipid content around S proteins. Such lipid surroundings may be necessary for virion entry. During the enveloped-virus entry process, there is a concerted refolding of the surface glycoproteins mediating membrane fusion (17). While the details of the refolding process are not yet known for coronavirus S proteins, the reaction fits the model for “class 1” viral fusion proteins (4). In this model, hydrophobic peptides move from the interior of the proteins and insert in cellular membranes, and then the proteins refold into end-stage structures, bringing the cell membrane-intercalated peptides toward the virion membrane to create the proximities necessary for cell-virion membrane fusion. This refolding process depends that there be no impediments to juxtaposing hydrophobic S fusion peptides with S transmembrane spans. Coronavirus assembly involves S-protein–M-protein interactions (11), while coronavirus entry demands that the M proteins not obstruct S-protein refolding. Our current view is that some S acylations create assembly competence, while other, additional S acylations might maintain other proteins, notably M, at an appropriate distance so that S protein refolding and membrane fusion reactions can be successfully completed.

ACKNOWLEDGMENTS

We thank Fumihiro Taguchi (National Institute of Neuroscience, Tokyo, Japan) and John Fleming (University of Wisconsin) for anti-S and anti-M antibodies. We thank Paul Masters (Wadsworth Center, New York State Department of Health) and Stanley Perlman (University of Iowa) for the plasmid vectors used to create recombinant mutant MHVs. We also thank Chandra Tangudu, Heidi Olivares, and Stanley Perlman for their comments during the preparation of the manuscript.

This work was supported by NIH grant 60030.

REFERENCES


